Designing Patient Hubs Purpose-Built for Cell and Gene Therapies
This Pharmaceutical Commerce article explores how purpose‑built patient hubs can streamline access, reduce barriers and better support the complex needs of cell and gene therapy patients. It was co‑authored by Ela Lourido, vice president and general manager of Biologics by McKesson, and Joe DePinto, head of cell, gene and advanced therapies for InspiroGene by McKesson.
How Proactive Specialty Pharmacy Care Helps Prevent Medication Waste
Read about how Biologics by McKesson uses proactive pharmacy care and personalized support to help patients stay on therapies, reduce costs and improve outcomes.
The Future of Oncology is Personal, and It’s Already Here
Learn how McKesson connects biopharma, providers and patients to deliver precision oncology at scale through integrated logistics, specialty pharmacy and high‑touch support.
AUGTYRO™ (Repotrectinib), FDA Approved for Treatment of AdvancedROS1-Positive & NTRK-Positive NSCLC, Available at Biologics by McKessonSpecialty Pharmacy in Limited Distribution Network
Biologics by McKesson joined the limited distribution network for AUGTYRO, approved for ROS1-positive non-small cell lung cancer and certain NTRK gene fusion-positive solid tumors.
IBTROZI™ (Taletrectinib), FDA-Approved Treatment, Available at Biologics by McKesson
Biologics by McKesson was selected as a limited specialty pharmacy provider for IBTROZI, a next-generation ROS1 inhibitor for adults with locally advanced or metastatic ROS1-positive non-small cell lung cancer.
EMRELIS™ (telisotuzumab vedotin-tllv), FDA Approved for Treatment of Adult Patients with Previously Treated Non-Small Cell Lung Cancer, Available Exclusively at Biologics by McKesson
Biologics by McKesson became the exclusive specialty pharmacy provider for EMRELIS, a first-in-class intravenous therapy for previously treated non-squamous NSCLC with high c-Met protein overexpression.
AVMAPKI™ FAKZYNJA™ CO-PACK (avutometinib capsules; defactinib tablets,) FDA Approved for the Treatment of Adult Patients with KRAS-Mutated Recurrent Low-Grade Serous Ovarian Cancer who have Received Prior Systemic Therapy, Available at Biologics by McKesson
Biologics by McKesson was selected as a limited specialty pharmacy provider for AVMAPKI FAKZYNJA CO-PACK, approved for adults with KRAS-mutated recurrent low-grade serous ovarian cancer after prior systemic therapy.
VANRAFIA (atrasentan), FDA Approved for Adults with Immunoglobulin A Nephropathy, Available at Biologics by McKesson
Biologics by McKesson was selected as a limited specialty pharmacy provider for VANRAFIA, adding a treatment option for adults with immunoglobulin A nephropathy.
GOMEKLI FDA Approved for Treatment of neurofibromatosis type 1-associated plexiform neurofibromas (NF1-PN), Available at Biologics by McKesson
Biologics by McKesson joined a limited distribution network for GOMEKLI, the first FDA-approved treatment for adults and children with NF1-associated plexiform neurofibromas not amenable to complete resection.
Romvimza (vimseltinib), FDA Approved for Treatment of Tenosynovial Giant Cell Tumor (TGCT), Available at Biologics by McKesson
Biologics by McKesson was selected as a distribution specialty pharmacy provider for ROMVIMZA, approved for adults with symptomatic tenosynovial giant cell tumor when surgery could cause severe morbidity.